Literature DB >> 15755472

Drug dosing in chronic kidney disease.

Steven Gabardi1, Stuart Abramson.   

Abstract

Patients with chronic kidney disease (CKD) are at high risk for adverse drug reactions and drug-drug interactions. Drug dosing in these patients often proves to be a difficult task. Renal dysfunction-induced changes in human pathophysiology regularly results may alter medication pharmacodynamics and handling. Several pharmacokinetic parameters are adversely affected by CKD, secondary to a reduced oral absorption and glomerular filtration; altered tubular secretion; and reabsorption and changes in intestinal, hepatic, and renal metabolism. In general, drug dosing can be accomplished by multiple methods; however, the most common recommendations are often to reduce the dose or expand the dosing interval, or use both methods simultaneously. Some medications need to be avoided all together in CKD either because of lack of efficacy or increased risk of toxicity. Nevertheless, specific recommendations are available for dosing of certain medications and are an important resource, because most are based on clinical or pharmacokinetic trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755472     DOI: 10.1016/j.mcna.2004.11.007

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  19 in total

1.  Management of drug toxicity in patients with renal insufficiency.

Authors:  Claudio Ponticelli; Giorgio Graziani
Journal:  Nat Rev Nephrol       Date:  2010-06       Impact factor: 28.314

2.  Treating epilepsy in the setting of medical comorbidities.

Authors:  Nivedita U Jerath; Dronacharya Lamichhane; Madhu Jasti; Vinusha Yarlagadda; Eduardo Zilli; Yara Nazzal; Mark Granner
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

Review 3.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

4.  Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.

Authors:  Malcolm J D'Souza; Ghada J Alabed
Journal:  Pharm Rev       Date:  2010-02-03

5.  Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.

Authors:  Meletios Dimopoulos; David Siegel; Darrell J White; Ralph Boccia; Karim S Iskander; Zhao Yang; Amy S Kimball; Khalid Mezzi; Heinz Ludwig; Ruben Niesvizky
Journal:  Blood       Date:  2018-11-26       Impact factor: 22.113

6.  Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.

Authors:  Dmytro Khadzhynov; Torsten Slowinski; Ina Lieker; Hans-Hellmut Neumayer; Diego Albrecht; Henk Johan Streefkerk; Sam Rebello; Harm Peters
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

7.  Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.

Authors:  Denise Morris; Joseph Podolski; Alan Kirsch; Ronald Wiehle; Lawrence Fleckenstein
Journal:  AAPS J       Date:  2011-10-25       Impact factor: 4.009

8.  Use of renal risk drugs in patients with renal impairment.

Authors:  Hilde Holm; Kirsti Bjerke; Lone Holst; Liv Mathiesen
Journal:  Int J Clin Pharm       Date:  2015-08-18

Review 9.  Estimating renal function to reduce the risk of adverse drug reactions.

Authors:  Andrea Corsonello; Graziano Onder; Silvia Bustacchini; Mauro Provinciali; Sabrina Garasto; Pietro Gareri; Fabrizia Lattanzio
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

10.  Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.

Authors:  Sujata Vaidyanathan; Hilde Bigler; ChingMing Yeh; Marie-Noelle Bizot; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.